Quratusugene Ozeplasmid for Small Cell Lung Cancer Receives Orphan Drug Designation by FDA
Genprex, Inc. is a clinical-stage gene therapy company and has announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the drug, Reqorsa Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer. Earlier in June 202e, FDA granted Fast Track Designation for Reqorsa Immunogene Therapy, in
